Major Investors Retreat from UnitedHealth as Medical Costs Surge

A significant shift is occurring among UnitedHealth’s shareholder base, with institutional money managers leading a substantial sell-off. Recent regulatory filings reveal that several major investment firms have dramatically reduced their stakes in the healthcare giant, creating uncertainty about the company’s near-term prospects. This institutional exodus comes as UnitedHealth shares have declined approximately 40% since the start of the year, prompting questions about what’s driving professional investors away.

Medical Cost Ratio Reaches Critical Levels

The primary concern centers on UnitedHealth’s Medical Care Ratio (MCR), which measures the percentage of premium revenue spent on medical services. This key metric has deteriorated alarmingly, climbing from a stable 82% in 2022 to a troubling 88% by the end of 2025. This 600-basis-point explosion in medical costs is significantly impacting profitability.

The cost surge stems primarily from increased utilization of medical services by Medicare Advantage members. This challenging environment forced management to substantially reduce full-year earnings guidance to approximately $16.25 per share, far below original expectations approaching $30 per share.

Institutional Selling Intensifies

Recent transactions highlight the growing caution among professional investors. Baltimore Washington Financial Advisors decreased its position by 6.3%, disposing of 1,582 shares. Even more dramatically, Financial Advocates Investment Management sold 1,510 shares, representing a substantial 40.1% reduction in their holdings.

Should investors sell immediately? Or is it worth buying Unitedhealth?

These moves indicate that seasoned wealth managers are reassessing UnitedHealth’s risk-reward profile. However, not all institutions are retreating. Bell Asset Management increased its holdings by 7.8%, building a position of nearly 28,000 shares. This divergence underscores the current market uncertainty, with some investors exiting while others identify potential value.

Valuation Presents Competing Narratives

UnitedHealth’s current valuation presents conflicting interpretations. Trading at a price-to-earnings multiple of approximately 17, the stock sits notably below its historical average range of 24-26. This discounted level has generated divided analyst opinions.

JPMorgan Chase maintains a $425 price target, suggesting nearly 29% upside potential from current levels. Conversely, Oppenheimer remains cautious with a $325 target, positioning it close to the present trading range. The central question remains when the Medical Care Ratio will stabilize, as continued volatility appears likely without clear signals of moderating medical expenses.

The recent institutional selling wave sends an unambiguous message: many professional investors lack the patience to await a potential recovery, choosing instead to reallocate capital elsewhere amid ongoing cost pressures.